Prospective vaccine prepared from a new mutant of Toxoplasma gondii for use in cats.
Kittens are the principal disseminators of Toxoplasma gondii. They can shed greater than 10(8) oocysts in the feces after initial infection with bradyzoites in tissue cysts. Thereafter, most kittens develop protective immunity and do not shed oocysts again if they are reinfected. Bradyzoites of a T gondii mutant, designated T-263, were used to vaccinate kittens. Their use did not result in oocyst shedding, but successfully prevented 84% (31/37) of the kittens from shedding oocysts when challenge exposed with a normal isolate of T gondii. Vaccination of outdoor-roaming cats and kittens would be a useful public health measure to prevent transmission of toxoplasmosis near homes, on farms, and in zoos. It is anticipated that several years will be required for a lyophilized bradyzoite vaccine to be ready for licensing and possible commercial availability.
Frenkel
J K
JK
Department of Pathology and Oncology, University of Kansas Medical Center, Kansas City 66103.
Pfefferkorn
E R
ER
Smith
D D
DD
Fishback
J L
JL
D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis; D002371:Cat Diseases / Q000517:prevention & control*; D002415:Cats; D005260:Female; D008297:Male; D016296:Mutagenesis; D016052:Protozoan Vaccines / Q000276:immunology; D014122:Toxoplasma / Q000235:genetics / Q000276:immunology*; D014124:Toxoplasmosis, Animal / Q000517:prevention & control*; D014611:Vaccination / Q000662:veterinary*
D000913:Antibodies, Protozoan; D016052:Protozoan Vaccines